Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, K. B. Nolop, Elizabeth A. Burton et al.|Nature|2010Cited by 1.8k
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFPoulikos I. Poulikakos, Neal Rosen, Chao Zhang et al.|Nature|2010Cited by 1.8k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsFei Su, Jeffrey A. Sosman, Amaya Virós et al.|New England Journal of Medicine|2012Cited by 1k
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerEric W. Joseph, Neal Rosen, Christine A. Pratilas et al.|Proceedings of the National Academy of Sciences|2010Cited by 447
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma modelDaniele Perna, David J. Adams, Florian A. Karreth et al.|Proceedings of the National Academy of Sciences|2015Cited by 143